Lap-Band Gains Panel Support For Use In Less Obese, Less Sick Patients
This article was originally published in The Gray Sheet
Executive Summary
An FDA panel has cleared the path for the agency to approve an expanded indication for Allergan's Lap-Band surgical obesity treatment to include at least 27 million additional people.
You may also be interested in...
IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.
IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.
News In Brief
Allergan’s Lap-Band